anticoagulation has come of age
generation XARELTO
®
SIX INDICATIONS STRONG
To reduce the risk of stroke and systemic embolism
in patients with nonvalvular atrial fibrillation (AF).
There are limited data on the relative effectiveness
of XARELTO® and warfarin in reducing the risk of
stroke and systemic embolism when warfarin therapy
is well controlled
For the treatment of pulmonary embolism (PE)
For the treatment of deep vein thrombosis (DVT)
For the prophylaxis of DVT, which may lead to PE in
patients undergoing hip replacement surgery
IMPORTANT SAFETY INFORMATION (cont’d)
CONTRAINDICATIONS
Active pathological bleeding
Severe hypersensitivity reaction to XARELTO®
(eg, anaphylactic reactions)
WARNINGS AND PRECAUTIONS
Increased Risk of Thrombotic Events After Premature
Discontinuation: Premature discontinuation of any oral
anticoagulant, including XARELTO®, in the absence of
adequate alternative anticoagulation increases the risk of
thrombotic events. An increased rate of stroke was observed
during the transition from XARELTO® to warfarin in clinical
trials in atrial fibrillation patients. If XARELTO® is discontinued
for a reason other than pathological bleeding or completion
of a course of therapy, consider coverage with another
anticoagulant.
Risk of Bleeding: XARELTO® increases the risk of bleeding and
can cause serious or fatal bleeding. Promptly evaluate any
signs or symptoms of blood loss and consider the need for
blood replacement. Discontinue XARELTO® in patients with
active pathological hemorrhage.
• A specific antidote for rivaro